Plasma sCD28, sCTLA-4 levels in neuromyelitis optica and multiple sclerosis during relapse
Authors:
Open Access
- 19 December 2011
- journal article
- research article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 243 (1-2) , 52-55
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Aberrant production of soluble co-stimulatory molecules CTLA-4 and CD28 in patients with chronic hepatitis BMicrobial Pathogenesis, 2011
- Neuromyelitis optica: Concepts in evolutionJournal of Neuroimmunology, 2011
- Cellular mechanisms of IL‐17‐induced blood‐brain barrier disruptionThe FASEB Journal, 2009
- Prediction of acute multiple sclerosis relapses by transcription levels of peripheral blood cellsBMC Medical Genomics, 2009
- Soluble costimulatory factors sCD28, sCD80, sCD86 and sCD152 in relation to other markers of immune activation in patients with myasthenia gravisJournal of Neuroimmunology, 2007
- Plasma concentrations of soluble CTLA‐4, CD28, CD80 and CD86 costimulatory molecules reflect disease severity of acute asthma in childrenPediatric Pulmonology, 2006
- IFN-β treatment modulates the CD28/CTLA-4-mediated pathway for IL-2 production in patients with relapsing -remitting multiple sclerosisMultiple Sclerosis Journal, 2004
- Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosisClinical and Experimental Immunology, 2004
- The two-signal model of lymphocyte activation twenty-one years laterImmunology Today, 1992
- Phenotypic and functional analysis of T cells cloned directly from the blood and cerebrospinal fluid of patients with multiple sclerosisAnnals of Neurology, 1985